Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 2/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9577691 | 0.96 | PGD (0.37) | PGDMPIBTN3A1 | |
| SCHEMBL5454027 | 0.96 | LMNA (0.41) | PGDMPIBTN3A1 | |
| SCHEMBL1160489 | 0.93 | LMNA (0.38) | PGDMPIBTN3A1 | |
| SCHEMBL3744513 | 0.89 | PGD (0.41) | PGDMPIBTN3A1 | |
| Phytate SCHEMBL9580721 | 0.88 | ITPR3 (0.33) | BTN3A1 | |
| SCHEMBL5525102 | 0.87 | PGD (0.48) | PGDMPI | |
| SCHEMBL9577589 | 0.85 | PGD (0.39) | PGDMPIBTN3A1 | |
| SCHEMBL3745928 | 0.85 | PGD (0.39) | PGDMPIBTN3A1 | |
| SCHEMBL630930 | 0.84 | PGD (0.53) | PGDMPI | |
| SCHEMBL21610 | 0.84 | PGD (0.53) | PGDMPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114948992-A | Amorphous calcium carbonate for the treatment of leukemia | 艾玛菲克有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-10329575-B2 | Regulatory sequence for plants | CERES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180223303-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | CERES INC (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170037426-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI (US) | 2017-02-09 | — | — | US | disclosed |
| US-20160076046-A1 | PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES THEREOF | CERES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9029523-B2 | Promoter, promoter control elements, and combinations, and uses thereof | CERES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150033417-A9 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI (US) | 2015-01-29 | — | — | US | disclosed |
| US-8877916-B2 | Promoter, promoter control elements, and combinations, and uses thereof | CERES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120159672-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | CERES, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120084885-A1 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI (US) | 2012-04-05 | — | — | US | disclosed |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI | 2011-08-04 | — | — | US | disclosed |
| US-20100037355-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | CERES, INC (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090265815-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded therapy | ALEXANDROV NICKOLAI | 2009-10-22 | — | — | US | disclosed |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | CERES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20060150283-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI | 2006-07-06 | — | — | US | disclosed |
| US-20060048240-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037426-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | PGD 3517/4885MPI 222/4885BTN3A1 1604/4885 |
| US-20150033417-A9 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | PGD 3339/4885MPI 348/4885BTN3A1 2140/4885 |
| US-20120084885-A1 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | PGD 3368/4885MPI 350/4885BTN3A1 2151/4885 |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | PGD 3517/4885MPI 222/4885BTN3A1 1604/4885 |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | PGD 3339/4885MPI 348/4885BTN3A1 2140/4885 |
| US-20120159672-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | PGD 3517/4885MPI 222/4885BTN3A1 1604/4885 |
| US-20100037355-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | RNGTT, CPSF1, CPSF6 | PGD 3517/4885MPI 222/4885BTN3A1 1604/4885 |
| US-20060048240-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | PGD 3517/4885MPI 222/4885BTN3A1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.